Applied BioCode (TPE:6598) LT-Debt-to-Total-Asset: 0.04 (As of Dec. 2025)

What is Applied BioCode LT-Debt-to-Total-Asset?

Applied BioCode TPE:6598 -0.87% 76 LT-Debt-to-Total-Asset is 0.04 as of Dec. 2025. GuruFocus rates TPE:6598 with a GF Score™ of 76/100 and a GF Value™ of NT$23.34 (Fairly Valued). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Applied BioCode's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.04.

Applied BioCode's long-term debt to total assets ratio increased from Dec. 2024 (0.00) to Dec. 2025 (0.04). It may suggest that Applied BioCode is progressively becoming more dependent on debt to grow their business.

Applied BioCode (TPE:6598) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Applied BioCode LT-Debt-to-Total-Asset Related Terms

Applied BioCode LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Applied BioCode's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Applied BioCode LT-Debt-to-Total-Asset Chart

Applied BioCode Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.03

0.02

0.00

0.04

Applied BioCode Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.00	0.01	0.04	0.04

76GF Score

Applied BioCode Corp TPE:6598

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Applied BioCode LT-Debt-to-Total-Asset Calculation

Applied BioCode's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	38.766	/	1012.704
	=	0.04

Applied BioCode's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	38.766	/	1012.704
	=	0.04

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.04 mean?

Applied BioCode (TPE:6598) has a LT-Debt-to-Total-Asset of 0.04 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Applied BioCode and its competitors.

Is Applied BioCode's LT-Debt-to-Total-Asset too high?

Applied BioCode's current LT-Debt-to-Total-Asset is 0.04. Overall, Applied BioCode has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Applied BioCode's LT-Debt-to-Total-Asset compare to ABT and SYK?

Applied BioCode's LT-Debt-to-Total-Asset of 0.04 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Applied BioCode and its competitors. Applied BioCode's current LT-Debt-to-Total-Asset is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Applied BioCode stock overvalued right now?

Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Fairly Valued. The stock's GF Value™ is NT$23.34, compared to a current price of NT$22.75 — trading 2.5% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.04. Applied BioCode's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current LT-Debt-to-Total-Asset is 0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Applied BioCode (TPE:6598) Overvalued in 2026?

Based on GuruFocus' analysis, Applied BioCode stock appears to be undervalued. The current stock price of NT$22.75 is trading 2.5% below its estimated GF Value™ of NT$23.34. GuruFocus considers Applied BioCode to be Fairly Valued.

Key valuation signals for TPE:6598:

LT-Debt-to-Total-Asset: 0.04
GF Value™: NT$23.34 vs. price of NT$22.75 (2.5% below fair value)
GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Applied BioCode Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies TPE:4106 TPE:6934 TPE:6796 TPE:6918 TPE:4155 ROCO:4138 ROCO:6649 TPE:6955 ROCO:7713 ROCO:4161 ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Address 12130 Mora Dr., Unit 2, Santa Fe Springs, CA, USA, 90670

Website https://www.apbiocode.com

Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.

76GF Score

Get the complete analysis for TPE:6598

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$22.75

Price

NT$23.34

GF Value

View TPE:6598 Analysis

See LT-Debt-to-Total-Asset data for all stocks →